First human test for new drug in kidney patients
NCT ID NCT06496217
Summary
This early-stage study aimed to understand how a new drug, MBX 2109, behaves in the body and how safe it is. It involved 25 adults, some with healthy kidneys and some with varying degrees of kidney impairment. Each participant received a single injection of the drug so researchers could measure how it was processed and cleared by the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MBX Bioscience Investigational Site
Tampa, Florida, 33603, United States
-
MBX Biosciences Investigational Site
Miami, Florida, 33136, United States
-
MBX Biosciences Investigational Site
Minneapolis, Minnesota, 55101, United States
Conditions
Explore the condition pages connected to this study.